Cruzipain (Cz), a key Trypanosoma cruzi enzyme, is a main candidate antigen for vaccines against Chagas' disease. We evaluated a vaccination protocol based on intradermal priming with recombinant Cz and intranasal boosting with rCz co-administered with a derivative of the TLR2/6 agonist MALP-2. Vaccination triggered strong systemic and mucosal antibody responses, and a vigorous cell-mediated immunity characterized by lymphoproliferation, DTH reactivity and IFN-γ production. The immune responses protected against a lethal trypomastigote challenge and, upon sub-lethal infection, immunized mice showed reduction of tissue damage and normal enzymatic markers of muscle injury. This prime-boost regimen appears promising for further development, since warranted survival, provided efficient control of parasite load and restricted inflammatory myopathy.
Introduction
Chagas' disease, or American trypanosomiasis, caused by the protozoan parasite Trypanosoma cruzi has a widespread distribution in America. An estimated 16 to 18 million persons are infected, and close to 100 million people are at risk of infection [1] . Transmission to humans occurs primarily through blood-sucking reduviid bugs, which deposit infective feces on the skin when they are feeding [2] . The disease is characterized by an initial acute phase during which trypomastigotes multiply in the blood, followed by an indeterminate phase with very low parasitemia and no apparent pathology. Susceptible hosts then enter a chronic phase with increasing tissue damage, mostly in cardiac and skeletal muscle tissues but sometimes also in the liver, spleen, colon, or esophagus, which progressively leads to cardiac failure and death [3] [4] [5] . There is still considerable debate about the mechanisms involved in Chagas disease's pathology.
Nevertheless, sensitive examination techniques confirmed that parasites persist in tissues and that there is a correlation between this persistence and tissue damage [10, 19, 20] . These results strongly encourage development of vaccines and new trypanocidal drugs directed to control T. cruzi infection in order to prevent or arrest Chagas pathogenesis.
Vaccines represent an outstanding success story in modern medicine and have had a dramatic effect on morbidity and mortality worldwide. Most of currently available vaccines are delivered through parenteral routes. However, mucosal vaccination offers several benefits, including higher acceptance by the public, easiness of administration, no risk of cross-contamination by infected needles, and more importantly, the induction of mucosal as well as systemic immunity, which might facilitate to block the agent at a very early stage of the infection process. Another attractive option for vaccine delivery is transcutaneous immunization. The skin, especially its epidermal layer, is an accessible and competent immune environment populated with Langerhans cells, which are efficient 3 and potent antigen-presenting cells. Induction of protective immunity may be accomplished by targeting antigens to the skin through intradermal (i.d.) injection or immunostimulant patches. The i.d. presentation of antigens to the immune system is able to raise a macrophage-dependent Tlymphocyte response via specific epidermal cells, which finally stimulates both T helper and cytolytic activities. Cross-presentation involves the uptake and processing of exogenous antigens within the major histocompatibility complex (MHC) class I pathway. This process primarily performed by CD8 + dendritic cells is likely to be important for the generation of cytotoxic T cell immunity [21] .
Considering that through mucosa or skin lesion T. cruzi finds its way to invade host cells, the elicitation of an effective immune response in those sites is highly desirable, as it may clearly contribute to control the infection at portal of entry. Several studies have focused on characterization of parasite antigens which may be used as vaccine candidates. In this regard, the major cysteine proteinase of T. cruzi, named cruzipain (Cz), has shown promise because it induced significant protection in mouse experimental models [22, 23] . In the present study, we evaluated whether intranasal (i.n.) and i.d. administration of recombinant Cz (rCz) combined with different synthetic adjuvants, namely oligodeoxynucleotides containing CpG motifs (CpG-ODN) and a derivative of a macrophage-activating lipopeptide from Mycoplasma fermentans (MALP-2), is able to confer protection against experimental T. cruzi infection. CpG-ODN are powerful enhancers of Th1 immune responses [23] [24] [25] through the activation of Toll-like receptor-9 (TLR-9)-dependent cascades [26] , whereas MALP-2 acts as a TLR-2/6 agonist [27, 28] improving humoral and cellmediated immunity. To further modulate and broaden the effective responses elicited, a prime-boost regimen including i.d. and mucosal rCz-based immunizations was also assessed.
Materials and methods

Parasites
T. cruzi epimastigotes (RA strain), were grown in biphasic medium as previously described [29] . Parasites were harvested during exponential growth phase by centrifugation at 5000 x g for 15 min and washed three times with 0.1 M phosphate buffered saline, pH 7.2 (PBS). Bloodstream trypomastigotes of the same parasite strain were isolated from acutely infected mice at the peak of parasitemia. 4 
Cruzipain cloning and expression
DNA from epimastigotes of T. cruzi (RA strain) was purified using the Genomic DNA extraction kit (QIAgen, Valencia, CA). Isolated DNA was used as a template for PCR amplification using a forward primer 5´-CATGGGATCCGCGCCCGCGGCAGTGGATTG-3´, with the BamH I site underlined, and a reverse primer 5´-CGCGCGCTCGAGGCGGCGATGACGGC-3´, with an Xho I site underlined. PCR was performed using Platinum Pfx (Invitrogen, Carlsbad, CA) DNA polymerase with an annealing temperature of 55ºC. The amplified 1037 bp fragment (encompassing bp 367 to 1404 of the sequence; accession number AF265226) was ligated into a prokaryotic expression plasmid (pET-23a) and used for transforming Escherichia coli DH5 host cells. After The cells were stirred at room temperature for 60 min and then centrifuged at 10,000 x g for 20 min
to pellet cellular debris.
rCz was purified under denaturing conditions by affinity chromatography using a Ni
2+
-NTA sepharose matrix. After several washes in lysis buffer pH 6.3, the protein was eluted at pH 5.5.
Properly folded rCz was obtained by extensive dialysis against PBS and stored at -70ºC until use.
Purity assessed by SDS-PAGE was >98%. Endotoxin was removed by a column of polymyxin B was synthesized according to established protocols [30] , and 0.5 μg/dose of the active moiety was employed where indicated.
Endotoxin was undetectable (<10 EU/mg) in both adjuvant preparations, as determined by the Limulus test.
Immunizations and challenge
All studies were carried out in inbred female 6-8 week-old C3H/HeN mice breed at the University of Buenos Aires, using 18 animals in each group which were maintained under standard conditions. Mice were immunized with the following formulations: PBS (GI) as control; rCz-CpG- 
Antibody determination
Serum Cz-specific antibody titers were determined by ELISA, as previously described [22] . The amount of Cz-specific IgA present in bronchial lavages was determined as previously described [27] .
To compensate for variations in the efficiency of recovery of secretory antibodies among animals, the Cz-specific IgA in each sample was normalized with the total amount of IgA present in the 6 lavage. Total IgA was detected by ELISA using plates coated with anti-IgA antibodies (Sigma) and purified IgA (Sigma) for the generation of the standard curve.
Delayed-type hypersensitivity (DTH) reactions
The DTH test was performed 13 days after the last immunization by i.d. challenge with 5 μg of rCz in the left footpads. The thickness of hind footpads was measured before and 48 h after the injection of the antigen with a Digital Indicator (Schwyz). Results are expressed as the difference in thickness of footpads after and before the inoculation
Proliferation assays and cytokine quantification
Spleen cells from controls and immunized mice were aseptically removed and cell suspensions were prepared. Cell proliferation was assayed as previously reported [22] . The production of cytokines in spleen cell supernatants was determined by capture ELISA (R&D System, Minneapolis,
To determine the number of IFN-γ-secreting CD8 + T cells, splenocytes were negatively enriched by using anti CD4 beads (Dynal Biotech, Hamburg, Germany). Then, a murine IFN-γ ELISPOT kit (BD Biosciences, San Jose, CA) was used according to manufacturer's instructions.
Colored spots were counted with a C.T.L. ELISPOT reader and analyzed using the ImmunoSpot image analyzer software v3.2. These results are expressed as Stimulation Index, which represents the relationship between the number of spots per well in presence of antigen and the number of spots per well with medium alone.
Measurement of muscle damage
Muscle injury was evaluated through the determination of a panel of myopathy-linked enzyme markers. Serum levels of creatine kinase (CK), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) were measured at 100 days post infection (dpi). The assays were done by ultraviolet spectrophotometry following the specifications of the manufacturer (Wiener Lab, Buenos
Aires, Argentina).
The histological features of heart and skeletal (quadriceps) muscles from vaccinated and infected mice (100 dpi) were also investigated. The removed organs were rinsed with PBS, fixed for 24 h in 10% buffered formalin, embedded in paraffin, sectioned, stained with hematoxilin-eosin, and 7 examined by light microscopy. A blind histological test was done, analyzing ten microscopic fields in ten sections of each organ.
9. Statistics
Statistical analyses were carried out with the Prisma 3.0 Software (GraphPad, San Diego, California) using one-way analysis of variance (ANOVA) for proliferation, cytokine, antibody and enzyme assays, and parasitemia data. Long rank test was used for survival curves. All the comparisons were referred to control group immunized with PBS (GI), except when indicated.
Values of p < 0.05 were considered significant.
Results
Cloning, characterization and expression of Cz
The genomic DNA from RA strain epimastigotes was extracted, a segment encompassing base pairs 367 to 1404 of the gene coding for Cz was PCR amplified and cloned in the pET23a vector.
Nucleotide sequencing showed more than 98% homology with previously reported Cz gene sequences. It is important to mention that Cz is a T. cruzi glycoprotein encoded by members of the cruzipain gene family, which has been shown to consist of up to 130 genes [31] . Affinity chromatography with a Ni 2+ -NTA agarose resin led to the purification of proteins with sizes of 50-60 kDa from pET23a-Cz transformed E. coli BL21-D3 strain (Fig. 1A) . Although the predicted molecular weight of Cz from amino acid sequence is 36.4 kDa, it has been reported that both native -NTA-HRP, QIAgen), which detects 6xHis-tagged proteins, and by polyclonal antibodies against native Cz (Fig. 1B) . Amino acid sequencing of the eight N-terminal residues confirmed the identity of the recombinant protein with Cz.
Cz immunization elicits strong antibody responses
We were observed in GII (6.82 ± 0.8 x 10 6 ), followed by GIII (4.7 ± 0.4 x 10 5 ) and GIV (1.3 ± 0.3 x 10 5 ). Conversely, mice vaccinated just by i.n. route (GV) did not display significant specific IgG titers. We then evaluated whether the different vaccination regimes were able to stimulate anti-Cz mucosal immunity by determining IgA in bronchial lavages (Fig. 2B) . Increased levels of Czspecific sIgA could only be demonstrated in samples from i.n. immunized mice. Remarkably, we observed a stronger response of Cz-specific sIgA in mice primed by i.d. route with rCz and boosted by i.n. route with rCz-MALP-2 (GIV), as compared to mice intranasally immunized with rCz-MALP-2 (GV). This difference could be explained considering that the B cells intradermally primed with rCz switched from IgG producers, as shown in Fig. 2A GIII, to IgA producers, when mice were boosted intranasally with rCz-MALP-2.
Efficient cellular immune responses are stimulated by the prime-boost vaccination protocol
In order to investigate in vivo whether inoculation of Cz elicited cellular immunity, we performed skin tests on vaccinated mice to evaluate the delayed-type hypersensitivity developed by the immunization protocols. Only animals primed intradermally with rCz and boosted with rCz-MALP-2 by i.n. route (GIV) displayed significant DTH response (p < 0.01, Fig 3A) . Additionally, lymphoproliferative assays were carried out in vitro to evaluate and compare the efficacy of the different vaccination protocols in inducing cell-mediated immune response. An increased cell proliferation was observed in mice vaccinated according to the prime-boost vaccination protocol (GIV), with respect to the control groups (p < 0.01, Fig 3B) . Spleen cells from control mice did not proliferate in response to rCz, but responded to ConA mitogenic stimulus, as expected (data not shown).
The rCz-based prime-boost immunization protocol induces a Th1-biased response
To evaluate the effect of the vaccination strategy on the elicited T helper response, we analyzed the predominance of the IgG1 or IgG2a subclass -representative of Th2-and Th1-type immunity, respectively-within the pool of rCz-specific serum antibodies (Fig. 4) . As previously reported by our group when native Cz was employed [22] IgG2a: 2.6 ± 1.5 x 10 4 , Fig 4) . In correspondence to what observed for total IgG (Fig. 2) , administration of rCz-MALP-2 by i.n. route (GV) promoted negligible IgG1 and IgG2a responses (Fig. 4) .
Cytokine profiles of rCz-vaccinated mice were also determined. To this end, we quantified by Fig 6) .
The prime/boost immunization protocol protects mice against T. cruzi infection
To determine whether the different strategies could induce immunoprotection against T. cruzi, 15 days after the last immunization mice were challenged with bloodstream trypomastigotes and individual parasitemia levels were assessed every other day.
When we inoculated mice with a lethal dose of live parasites, a significant (p < 0.05) reduction in the level of circulating trypomastigotes was recorded for GIV throughout the acute phase of infection and particularly at the peak of parasitemia (4.9 ± 0.9 x 10 5 parasites/ml in GIV vs. 1.9 ± 0.4
x 10 6 parasites/ml in controls, at 14 dpi; Fig 7A) . Most importantly, in mice immunized with the prime-boost regimen (GIV) there was an important delay in the mean time to death, with a 60% survival rate at the end of experiment (100 dpi), compared to the remaining groups that died at 14-27 dpi (Fig 7B) .
In another experimental setting with groups of mice immunized as previously, a sub-lethal model of murine T. cruzi infection was established after vaccination. When we analyzed the area under the parasitemia curve in all immunization groups, we observed an important decrease in the number of circulating parasites (2 to 4 times lower comparing with control group), with a significant (p < 0.01) reduction at the peak of parasitemia on day 23 (Fig 8) . Thus, we further investigated whether the immunization regimes capable of reducing parasitemia were additionally effective in limiting tissue injury, particularly cardiac muscle damage, a pathognomonic feature of chronic Chagas' heart disease. Accordingly to the known limited parasitism in murine heart upon infection with the RA strain, we were unable to identify by microscopic examination of stained tissue sections any abnormality in the myocardial tissues from either rCz-immunized or control groups. We then analyzed a more sensitive marker of muscle damage, by measuring serum levels of the cardiomyopathy-associated enzymes (i.e., CK, LDH and AST) in infected mice at 100 dpi.
Immunized and challenged mice exhibited a marked decrease of circulating enzymes compared with the levels observed in non-immunized infected controls. Although this reduction was observed in all groups, it was strikingly remarkable in mice subjected to the rCz prime-boost protocol, where a 6-7
fold-decrease respect to controls was observed (Fig 9) . It is noteworthy that mice immunized following that regimen presented serum enzyme levels similar to basal values recorded in untreated mice (28.67 ± 10.41, 1087 ± 240 and 8.6 ± 4.6 for CPK, LDH and AST, respectively). These results were in agreement with the histopathologic analysis of skeletal muscles, in which mice that received rCz prime-boost protocol exhibited negligible myopathy, in opposition to the inflammatory foci and fiber muscle infarction observed in the quadriceps from control animals and mice in the remaining vaccinated groups ( Table 1 ).
Discussion
There is an increasing need for novel vaccines able to stimulate efficient and long-lasting responses for the prevention of infectious diseases. In the case of Chagas' disease, chemotherapeutic agents have limited effectiveness against chronic T. cruzi infection, and no prophylactic vaccines are currently available. Studies in experimental models have delineated the effector mechanisms that are essential to provide resistance to T. cruzi infection. Several well-defined vaccine candidate antigens are known to elicit partially protective immunity against this protozoan parasite. These include Cz, the major cystein proteinase of T. cruzi [22] . This enzyme is expressed in all strains and developmental forms of the parasite (epimastigote, amastigote and trypomastigote), it is accumulated in lysosomes, is secreted and it is also present at surface level, being able to hydrolyse IgG [33] .
Moreover, specific enzyme inhibitors interfere with cell invasion and T. cruzi replication [34] . In vitro, it has been shown that Cz is capable of modulating the immune response towards a type-2 profile by increasing IL-10 and TGF-β secretion, while simultaneously decreasing the production of IL-12 [35] . In vivo it has been shown that the administration of IL12 and anti-IL4 is able to modulate the profile induced by Cz from predominantly a Th2/3 to a Th1, and this switch leads to control the infection [23] . Nevertheless, the administration of interleukins or antibodies against them is not a useful approach for the development of human vaccines. We previously demonstrated that native Cz co-administered with ODN-CpG, was able to confer protection against a lethal challenge with trypomastigotes [22] ; but purification of native Cz is too laborious and costly, requires complex manufacturing, and the resulting product is considered unstable and too-expensive for vaccine development. Here, we were able to overcome this problem by the highly efficient expression and purification of rCz (13.5 mg per liter of bacterial culture).
In parallel with the attempts to identify vaccine candidates, further efforts are being focused on the identification of efficient antigen delivery systems, adjuvants and vaccination regimens to enhance the protective responses to defined immunogens. In the present study, we investigated whether the immunoprotective response previously reported by us using native Cz could be achieved with rCz. We also evaluated if the elicited responses can be modulated and broadened by the use of different adjuvants and inoculation routes. cruzi RA strain is known to produce limited cardiac parasitism in chronic murine infection [39] , we analyzed more sensitive and broader markers of muscle damage, by measuring the serum levels of the myopathy-associated enzymes CK, LDH and AST. Our rationale for choosing these enzymes was their abundant distribution in heart and muscles, and their increased serum activity in chronically infected hosts showing inflammatory damage [40] . We found significantly reduced enzyme activity in mice vaccinated using distinct immunizing strategies respect to non-vaccinated and infected animals. Remarkably, mice under the prime-boost regimen presented values as low as those detected in naive mice under basal conditions. Accordingly, rCz-vaccinated animals from this group presented no inflammatory infiltrates in their striated muscles. Encouraging results have also been recently reported by our group using Salmonella-mediated delivery of a Cz-based DNA vaccine [41] . However, it would be difficult to implement such approach in the field. The existence of pre-existing immunity to the carrier in the Chagas' disease endemic area, which could in turn affect the overall efficacy of the intervention, may represent a roadblock for mass implementation of a prophylactic vaccine. On the other hand, the potential risk of integration of DNA vaccines should be carefully evaluated in terms of cost-benefit, particularly for an intervention aimed at the pediatric population. Therefore, a simple and robust approach, such as the one described here, which is based on the use of a recombinant protein and a synthetic adjuvant with a well-defined molecular target appeals as easier to implement and more promising than DNA vaccines. experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001. 19 
